In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Virtual Nodule Clinic software in the USA.

Ryan Hennen (VP of US Sales) is a healthcare sales professional who brings twenty years’ experience consulting with large healthcare integrated delivery networks (IDNs) while helping deliver enterprise-wide solutions to healthcare. He has experience with imaging, oncology, value based care, population health, clinical decision support, artificial intelligence, natural language processing, and machine learning.  Ryan has worked in the medical device and information technology divisions of Canon / Toshiba and IBM Watson Health.

Ryan has joined Optellum as VP of US Sales and meets with clinicians and healthcare leadership teams to demonstrate the benefits of Optellum’s products and how they enable doctors to track more patients, make faster decisions and eliminate care variance.

Rhiannon Lassiter (Head of Marketing and Communications) has fifteen years’ experience in marketing and communications in higher education and healthcare, working to promote teaching, learning and new technologies. She created the first Virtual Open Day at Oxford Brookes in 2014 and was co-founder of the UK’s Higher Education Customer Relationship Management network. Recently she worked as part of a digital innovation catalyst team at Oxford University Hospitals NHS Foundation Trust. She is a published author of fourteen science fiction and other speculative fiction titles and has an MA from the University of Oxford where she read English Literature and two NVQs in management.

Her role at Optellum is the creation of the marketing and communications strategy and the delivery of an operational plan to support the commercialisation of the company’s products.

Dr Johnathan Watkins (VP of Market Access and Clinical Research) has ten years of experience in management consulting, academic research, and product management, specialising in healthcare services and cancer genome bioinformatics. He read pre-clinical medicine focussing on Genetics at Cambridge University, holds a PhD in Cancer Research from King’s College London, and has published more than thirty peer-reviewed papers. At McKinsey & Co, he spent 3.5 years serving healthcare and life-science clients in the UK, US, and Europe, and helped drive the development of the UK healthcare practice’s data and analytics capabilities. In particular, he has supported healthcare payors, providers, and systems on topics including data strategy, value-based care and service redesign.

He currently drives Optellum’s market access activities and the evidence gathering to support those; working with societies and insurers to codify the benefits that Optellum brings to the care pathway.

Václav Potěšil (CEO) commented:

“These new appointments represent the investment we are putting into expanding the commercialization, in the wake of successful sales and clinical deployment of Optellum’s platform by the first wave of US customers. We have put a fantastic team in place to ensure the success of our company, and deliver on Optellum’s vision of enabling every lung cancer patient to have the best chance to fight back.”